On a sunny autumn day in Shanghai, NeuShen’s colleagues were delighted to host a special event that brought together many prominent figures in the scientific, medical, and investing communities. Pioneering gene therapy researcher Dr. Guangping Gao and renowned clinical expert Dr. Yifeng Shen gave insightful talks on latest developments in gene therapy and the current status of psychiatric diseases and CNS drug market in China respectively, leaving all attendees feeling optimistic about advancing research and treatments for CNS disorders. At NeuShen, we always believe in the vital role we should play in improving the lives of individuals affected by these illnesses and sharing this mission with our advocates. With the knowledge and inspirations gained from events like this, we are poised to make further strides in our mission to transform the landscape of CNS therapeutics!

About NeuShen Therapeutics

NeuShen Therapeutics is a global biotechnology company focused on innovative drug research and development to address neurological and psychiatric disorders, using a dual-platform strategy consisting of small molecule discovery and AAV-based gene therapy. With operations in Shanghai, China and Lexington, MA., NeuShen boasts a world-class R&D team in CNS field and is honored to be advised by an outstanding board of directors and scientific advisory board.